atients in AIDS Clinical Trial Group (ACTG) Study 193A were randomized to<br/>dual or triple combinations of HIV-1 reverse transcriptase inhibitors.<br/>Specifically, patients were randomized to one of four daily regimens containing<br/>600mg of zidovudine: zidovudine alternating monthly with 400mg didanosine;<br/>zidovudine plus 2.25mg of zalcitabine; zidovudine plus 400mg of didanosine;<br/>or zidovudine plus 400mg of didanosine plus 400mg of nevirapine (triple therapy).<br/>Measurements of CD4 counts were scheduled to be collected at baseline and at<br/>8-week intervals during follow-up. However, the CD4 count data are unbalanced<br/>due to mistimed measurements and missing data that resulted from skipped visits<br/>and dropout. The number of measurements of CD4 counts during the first 40<br/>weeks of follow-up varied from 1 to 9, with a median of 4.<br/>The response variable is the log transformed CD4 counts, log(CD4 counts +</div></div></td></tr></tbody></table></td></tr></tbody></table><a href="http://blog.sina.com.cn/u/1244765643"></a></p>
| 欢迎光临 数学建模社区-数学中国 (http://www.madio.net/) | Powered by Discuz! X2.5 |